entertainment -WSS

entertainment

author：entertainment 2025-09-30 00:35:08 - browse：4

Palm Drive at Stanford University on March 28, 2023 — Palm Drive at the entrance to Stanford University. Brian Frank for STAT

The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities in his past research marks more than just the startling downfall of the leader of one of the nation’s top research powerhouses. The case is likely to have broader repercussions, signaling a tipping point in an ongoing and often contentious debate about how to assign blame and credit in the increasingly collaborative world of research.

Science is a team sport. And while the lab leaders, or principal investigators, often get most of the attention for biomedical breakthroughs, they seldom run experiments. That work is left to postdoctoral researchers, graduate students, and others who peer through microscopes, labor away in mouse rooms, and spend countless hours pipetting. Instead, professors play more of a managerial role, supervising, critiquing, and offering big-picture feedback on the work that goes on in their lab.

It’s a longstanding arrangement, but one that leads to a thorny question when research is challenged: Who’s to blame? STAT put that question to Stanford faculty and students while reporting earlier this year on allegations of image manipulation and other misconduct related to research in Tessier-Lavigne’s lab, as well as researchers at other institutions. The answer varied depending on whom you asked.

Graduate students stressed that since faculty have no qualms using work done in their labs to land grants, win prizes, and build prestige, they should ultimately be accountable for problems with the science done under their supervision. Faculty generally agree, at least in principle, but are often quick to say that there are limits to how closely they can scrutinize their lab’s work, and that team science is in part based on trust. It’s an argument Tessier-Lavigne cited in his own statement about his resignation.

It’s also one he said wasn’t good enough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Bill would stop addiction treatment from triggering child abuse inquiry

focus

WSS

FDA greenlights medical device to combat bladder issues

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

FDA rejects Alnylam's heart disease treatment over insufficient data

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

A virus, fished out of a lake, may have saved a man’s life

Abortion policy in the spotlight at Republican debate

leisure time

entertainment

leisure time

The high cost of giving birth even with insurance

Physician executives need more than on

Affirmative action in medical school literally saved lives

Why age limits for politicians are a terrible idea

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What to expect at HLTH 2023, the health care industry conference

New air purifier tech could be key to improving indoor air quality

Wegovy improves function in certain heart failure patients

Affirmative action in medical school literally saved lives

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

focus

3 questions for the future of Biden's cancer moonshot

People can get long Covid without testing positive for virus: Study

Phenylephrine and the overlooked value of the placebo effect

How to make over

Phenylephrine and the overlooked value of the placebo effect

Analysis of telehealth claims data suggest service duplication

explore

focus

focus

hotspot